Tag - TRYP

Developments

FDA clears Tryp’s IND for Phase 2a IBS study at MGH

The FDA completed a review of Tryp Therapeutics’ (CSE:TRYP; OTCQB:TRYPF) investigational new drug application, permitting the company to proceed with a Phase 2a clinical trial at Massachusetts General Hospital (MGH)...

July 13, 2023

Developments

Tryp Therapeutics files IND for Phase 2a eating disorders study

Tryp Therapeutics (CSE TRYP; OTCQB:TRYPF) submitted an IND with the FDA to evaluate its clinical candidate, TRP-8802, in a Phase 2a study for the treatment of patients with eating disorders. The trial is being conducted...

September 23, 2021

Markets

Ladenburg starts Tryp Therapeutics at buy; PT $2

Ladenburg Thalmann initiated coverage of Tryp Therapeutics (OTCQB:TRYPF; CSE:TRYP) with a “buy” rating and $2 price target. The stock closed at 37 cents on Aug. 25. Tryp is focused on developing psychedelic...

August 26, 2021

Developments

Tryp Therapeutics, Calvert Labs in pact to study psilocybin formulations

Tryp Therapeutics (CSE:TRYP; OTCQB:TRYPF) agreed with Calvert Labs, an Altasciences company, to design and execute exploratory studies related to Tryp’s psilocybin-for-neuropsychiatric disorders (PFN) program. The...

August 10, 2021

Tag - TRYP

FDA clears Tryp’s IND for Phase 2a IBS study at MGH

Tryp Therapeutics files IND for Phase 2a eating disorders study

Ladenburg starts Tryp Therapeutics at buy; PT $2

Tryp Therapeutics, Calvert Labs in pact to study psilocybin formulations

General

More